Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML [Yahoo! Finance]
Aptose Biosciences, Inc. - Common Shares (APTO)
Last aptose biosciences, inc. - common shares earnings: 3/10 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
aptose.com/investors
Company Research
Source: Yahoo! Finance
TUS-based therapies are active in FLT3 wildtype, representing ~70% of AML patients TUS Targets VEN Resistance Mechanisms, Enabling TUS+VEN to Achieve Responses in Difficult-to-treat Prior-VEN Failure AML SAN DIEGO and TORONTO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today featured a wealth of clinical data for Aptose's lead compound tuspetinib (TUS) in a poster presentation at the 66 th American Society of Hematology (ASH) Annual Meeting in San Diego. Poster title: “Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML” Key Findings and Messages: TUS+VEN+AZA
Show less
Read more
Impact Snapshot
Event Time:
APTO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APTO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APTO alerts
High impacting Aptose Biosciences, Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
APTO
News
- Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Aptose Announces Positive Decision by Nasdaq Hearings Panel [Canadian Business Journal (Canada)]Canadian Business Journal
- Aptose Announces Positive Decision by Nasdaq Hearings Panel [Yahoo! Finance]Yahoo! Finance
- Aptose Announces Positive Decision by Nasdaq Hearings PanelGlobeNewswire
APTO
Earnings
- 8/8/24 - Beat
APTO
Sec Filings
- 12/30/24 - Form DEF
- 12/30/24 - Form DEFA14A
- 12/19/24 - Form 8-K
- APTO's page on the SEC website